![]() |
Data Presented At San Antonio Breast Cancer Symposium Demonstrate Treatment With Deno
Amgen (NASDAQ:AMGN) announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer...
More... |
| All times are GMT -7. The time now is 08:11 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021